STAT+: Up and down the ladder: The latest comings and goings

STAT PlusPharmalot Up and down the ladder: The latest comings and goings Manage alerts for this article Email this article Share this article By Ed SilvermanJuly 17, 2026 Pharmalot Columnist, Senior Writer Ed Silverman[email protected]Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week. This time around, we note that Ichnos Glenmark Innovation hired Mariana Cota Stirner as chief medical officer. Previously, she served as fractional chief medical officer and head of clinical development at Azalea Therapeutics. Before that, she was vice president and therapeutic area head of hematology at AbbVie.Advertisement But all work and no play can make for a dull chief medical officer. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, jobs, Pharmaceuticals, STAT+ Submit a correction requestReprints Ed Silverman Pharmalot Columnist, Senior Writer Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. STAT+ Newsletter Pharmalot columnist Ed Silverman rounds up the most important news of the day in the global drug industry Recommended Pharmalot July 17, 2026 STAT Plus: Pharmalittle: We’re reading about rising drug shortages, GSK coughing up a trial loss, and more Pharmalot July 16, 2026 STAT Plus: Pharmalittle: We’re reading about Kalshi bets on clinical trials, a Merck cholesterol pill, and more Advertisement Pharmalot July 15, 2026 STAT Plus: Bipartisan lawmakers want to require U.S. to probe reliance on foreign-made drugs, ingredients Pharmalot July 15, 2026 STAT Plus: Glenmark to pay $29.6 million to settle price-fixing allegations in long-running battle with states Pharmalot July 15, 2026 STAT Plus: Pharmalittle: We’re reading about a Biogen Alzheimer’s drug, skyrocketing 340B drug sales, and more Subscriber Picks